PMID- 31579241

OWN - NLM
STAT- PubMed-not-MEDLINE
LR - 20201001
IS - 0972-3919 (Print)
IS - 0974-0244 (Electronic)
IS - 0974-0244 (Linking)
VI - 34
IP - 4
DP - 2019 Oct-Dec
TI - Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed
Tomography
in a Giant Left Pectoral Muscle Plasmacytoma and Multiple Myeloma Case.
PG - 341-343
LID - 10.4103/ijnm.IJNM_83_19 [doi]
AB - Extramedullary plasmacytoma is an unusual manifestation in multiple myeloma
(MM).
It can present as a solitary bone lesion and/or soft-tissue mass.
Plasmacytoma
can be presented at any location, but it is more common in the head and neck,
usually without systemic involvement. The presence of plasmacytoma in MM is a
predictor of rapidly progressive disease. The value of
fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography
(PET)/computed
tomography (PET-FDG) is increasing, in the diagnosis, detection of occult
lesions, and therapeutic monitoring. We describe a patient with
rapidly-progressive, refractory, left pectoral muscle plasmacytoma and MM. A
PET-FDG guided the therapy and allowed to identify the presence of disease
relapse.
CI - Copyright: © 2019 Indian Journal of Nuclear Medicine.
FAU - Martínez-Amador, Néstor
AU - Martínez-Amador N
AD - Department of Nuclear Medicine, Valdecilla University Hospital, Molecular
Imaging
Group (IDIVAL), University of Cantabria, Santander, Spain.
FAU - Quirce, Remedios
AU - Quirce R
AD - Department of Nuclear Medicine, Valdecilla University Hospital, Molecular
Imaging
Group (IDIVAL), University of Cantabria, Santander, Spain.
FAU - Martínez-Rodríguez, Isabel
AU - Martínez-Rodríguez I
AD - Department of Nuclear Medicine, Valdecilla University Hospital, Molecular
Imaging
Group (IDIVAL), University of Cantabria, Santander, Spain.
FAU - Lucas-Velázquez, Blanca
AU - Lucas-Velázquez B
AD - Department of Nuclear Medicine, Valdecilla University Hospital, Molecular
Imaging
Group (IDIVAL), University of Cantabria, Santander, Spain.
FAU - Fernández-Martínez, Cristina
AU - Fernández-Martínez C
AD - Department of Hematology, Valdecilla University Hospital, University of
Cantabria, Santander, Spain.
FAU - Banzo, Ignacio
AU - Banzo I
AD - Department of Nuclear Medicine, Valdecilla University Hospital, Molecular
Imaging
Group (IDIVAL), University of Cantabria, Santander, Spain.
LA - eng
PT - Journal Article
PL - India
TA - Indian J Nucl Med
JT - Indian journal of nuclear medicine : IJNM : the official journal of the
Society
of Nuclear Medicine, India
JID - 8901274
PMC - PMC6771214
OTO - NOTNLM
OT - Extramedullary plasmacytoma
OT - fluorine-18-fluorodeoxyglucose positron emission tomography/computed
tomography
OT - intramuscular plasmacytoma
OT - multiple myeloma
OT - soft-tissue plasmacytoma
COIS- There are no conflicts of interest.
EDAT- 2019/10/04 06:00
MHDA- 2019/10/04 06:01
CRDT- 2019/10/04 06:00
PHST- 2019/10/04 06:00 [entrez]
PHST- 2019/10/04 06:00 [pubmed]
PHST- 2019/10/04 06:01 [medline]
AID - IJNM-34-341 [pii]
AID - 10.4103/ijnm.IJNM_83_19 [doi]
PST - ppublish
SO - Indian J Nucl Med. 2019 Oct-Dec;34(4):341-343. doi: 10.4103/ijnm.IJNM_83_19.

PMID- 32522411
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR - 20210610
IS - 2253-8089 (Electronic)
IS - 2253-8089 (Linking)
VI - 39
IP - 4
DP - 2020 Jul-Aug
TI - (18)F-FDG PET or PET/CT role in plasmacytoma: A systematic review.
PG - 220-224
LID - S2253-654X(19)30331-2 [pii]
LID - 10.1016/j.remn.2019.12.004 [doi]
AB - BACKGROUND: The metabolic behavior of plasmacytoma at (18)F-FDG PET/CT is not
yet
clear. OBJECTIVE: The aim of this systematic review was to analyze published
data
about the role of (18)F-FDG PET or PET/CT in patients affected by
plasmacytoma.
METHODS: Acomprehensive computer literature search of the Scopus,
PubMed/MEDLINE,
Embase and Cochrane Library databases was conducted including articles up to
July
2019 to find relevant published papers about the performance of (18)F-FDG PET
and
PET/CT in plasmacytoma. RESULTS: The comprehensive computer literature search
revealed 371 articles. On reviewing the titles and abstracts, 363 articles
were
excluded because the reported data were not within the field of interest of
this
 review. Eight articles were selected and retrieved in full-text version. From
the
analyses of the selected studies, the following main findings have been
founded:
1) plasmacytoma generally is a (18)F-FDG-avid tumor and PET/CT had good
diagnostic performance with high sensitivity; 2) (18)F-FDG PET/CT influenced
patient management in most cases avoiding useless therapies and choosing the
best
therapeutic approach; 3) prognostic value of PET/CT qualitative and
semiquantitative parameters is only suggested with controversial reports.
CONCLUSION: Despite several limitations affect this analysis, especially
related
to the low number of articles and patients studied, plasmacytoma looks to be
an
(18)F-FDG-avid tumor in most of the cases; (18)F-FDG PET or PET/CT had good
diagnostic performance and had a significant clinical impact in change of
therapeutic approach. Moreover, a possible prognostic role of PET/CT features
is
described.
CI - Copyright © 2020 Sociedad Española de Medicina Nuclear e Imagen Molecular.
Publicado por Elsevier España, S.L.U. All rights reserved.
FAU - Albano, D
AU - Albano D
AD - Nuclear Medicine, University of Brescia and Spedali Civili, Brescia, Italia.
Electronic address: [email protected].
FAU - Tomasini, D
AU - Tomasini D
AD - Department of Radiation Oncology, University of Brescia and Spedali Civili,
Brescia, Italia.
FAU - Bonù, M
AU - Bonù M
AD - Department of Radiation Oncology, University of Brescia and Spedali Civili,
Brescia, Italia.
FAU - Giubbini, R
AU - Giubbini R
AD - Nuclear Medicine, University of Brescia and Spedali Civili, Brescia, Italia.
FAU - Bertagna, F
AU - Bertagna F
AD - Nuclear Medicine, University of Brescia and Spedali Civili, Brescia, Italia.
LA - eng
LA - spa
PT - Journal Article
PT - Systematic Review
TT - Papel de la (18)F-FDG PET o PET/TC en el plasmocitoma: una revisión
sistemática.
DEP - 20200607
PL - Spain
TA - Rev Esp Med Nucl Imagen Mol (Engl Ed)
JT - Revista espanola de medicina nuclear e imagen molecular
JID - 101770941
RN - 0 (Fluorine Radioisotopes)
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN - GZ5I74KB8G (Fluorine-18)
SB - IM
MH - *Fluorine Radioisotopes/pharmacokinetics
MH - *Fluorodeoxyglucose F18/pharmacokinetics
MH - Humans
MH - Plasmacytoma/*diagnostic imaging/metabolism
MH - *Positron Emission Tomography Computed Tomography
MH - *Positron-Emission Tomography
MH - Prognosis
MH - Prospective Studies
MH - *Radiopharmaceuticals/pharmacokinetics
MH - Retrospective Studies
MH - Sensitivity and Specificity
MH - *Tomography, Emission-Computed, Single-Photon
OTO - NOTNLM
OT - (18)F-FDG
OT - PET/CT
OT - PET/TC
OT - Plasmacytoma
OT - Plasmocitoma
OT - Revisión sistemática
OT - Systematic review
EDAT- 2020/06/12 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/09/03 00:00 [received]
PHST- 2019/12/04 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - S2253-654X(19)30331-2 [pii]
AID - 10.1016/j.remn.2019.12.004 [doi]
PST - ppublish
SO - Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Jul-Aug;39(4):220-224. doi:
10.1016/j.remn.2019.12.004. Epub 2020 Jun 7.

PMID- 32139013
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR - 20210302
IS - 1532-1924 (Electronic)
IS - 1521-6926 (Print)
IS - 1521-6926 (Linking)
VI - 33
IP - 1
DP - 2020 Mar
TI - Current and potential applications of positron emission tomography for
multiple
myeloma and plasma cell disorders.
PG - 101148
LID - S1521-6926(20)30009-8 [pii]
LID - 10.1016/j.beha.2020.101148 [doi]
AB - Fluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET)
allows evaluation of elevated glucose metabolism in malignancies. There has
been
increasing interest in FDG PET/CT for plasma cell disorders since the
International Myeloma Working Group outlined multiple applications of this
imaging modality, including distinguishing smoldering myeloma from active
multiple myeloma, confirmation of solitary plasmacytoma, and multiple
indications
in patients with known multiple myeloma, including determining extent of
initial
disease, monitoring therapy response, and detection of residual disease
following
therapy. The field of molecular imaging is now shifting focus from evaluation
of
metabolism to targeted evaluation of specific tumor markers. Targeted PET
imaging
targeted of CXCR4 and CD38 has advanced into translational clinical trials,
bringing us closer to powerful imaging options for myeloma. In this review we
discuss the current applications of FDG PET/CT in plasma cell disorders, as
well
as advances in targeted PET imaging.
CI - Copyright © 2020. Published by Elsevier Ltd.
FAU - Ulaner, Gary A
AU - Ulaner GA
AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York,
NY,
10065, USA; Weill Cornell Medical College, New York, NY, 10065, USA.
Electronic
address: [email protected].
FAU - Landgren, C Ola
AU - Landgren CO
AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
10065, USA; Weill Cornell Medical College, New York, NY, 10065, USA.
Electronic
address: [email protected].
LA - eng
GR - P30 CA008748/CA/NCI NIH HHS/United States
PT - Journal Article
PT - Research Support, N.I.H., Extramural
PT - Research Support, Non-U.S. Gov't
PT - Review
DEP - 20200117
PL - Netherlands
TA - Best Pract Res Clin Haematol
JT - Best practice & research. Clinical haematology
JID - 101120659
RN - 0 (B-Cell Maturation Antigen)
RN - 0 (Biomarkers, Tumor)
RN - 0 (CXCR4 protein, human)
RN - 0 (Membrane Glycoproteins)
RN - 0 (Neoplasm Proteins)
RN - 0 (Radiopharmaceuticals)
RN - 0 (Receptors, CXCR4)
RN - 0 (TNFRSF17 protein, human)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN - EC 3.2.2.5 (CD38 protein, human)
RN - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB - IM
MH - ADP-ribosyl Cyclase 1/genetics/metabolism
MH - B-Cell Maturation Antigen/genetics/metabolism
MH - Biomarkers, Tumor/genetics/metabolism
MH - Bone Marrow/metabolism/pathology
MH - Disease Progression
MH - Fluorodeoxyglucose F18/*metabolism
MH - Gene Expression
MH - Humans
MH - Membrane Glycoproteins/genetics/metabolism
MH - Neoplasm Proteins/*genetics/metabolism
MH - Neoplasm, Residual
MH - Plasma Cells/metabolism/pathology
MH - Plasmacytoma/*diagnostic imaging/genetics/metabolism/pathology
MH - Positron Emission Tomography Computed Tomography/*methods
MH - Radiopharmaceuticals/metabolism
MH - Receptors, CXCR4/genetics/metabolism
MH - Smoldering Multiple Myeloma/*diagnostic imaging/genetics/metabolism/pathology
PMC - PMC7410322
MID - NIHMS1613293
OTO - NOTNLM
OT - 18F-fluorodeoxyglucose (FDG)
OT - Multiple myeloma
OT - Positron emission tomography (PET)
OT - immunoPET
EDAT- 2020/03/07 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - S1521-6926(20)30009-8 [pii]
AID - 10.1016/j.beha.2020.101148 [doi]
PST - ppublish
SO - Best Pract Res Clin Haematol. 2020 Mar;33(1):101148. doi:
10.1016/j.beha.2020.101148. Epub 2020 Jan 17.

PMID- 33813607
OWN - NLM
STAT- MEDLINE
DCOM- 20211130
LR - 20211130
IS - 1432-2161 (Electronic)
IS - 0364-2348 (Linking)
VI - 51
IP - 1
DP - 2022 Jan
TI - Role of FDG PET in the staging of multiple myeloma.
PG - 31-41
LID - 10.1007/s00256-021-03771-2 [doi]
AB - (18)F-Fluorodeoxyglucose (FDG) PET has been used for staging of hematologic
malignancies for years. In multiple myeloma, this imaging modality can be
used in
many different scenarios, including initial staging, evaluation of treatment
response, and investigation of residual disease or early relapse. FDG PET-CT
has
excellent diagnostic performance, similar to other advanced imaging
modalities
such as whole-body CT and MRI, and it is particularly helpful for the
assessment
of extramedullary disease. It also offers important prognostic information on
survival and risk of relapse, both at baseline and after therapy. This review
will cover the main applications, advantages, and limitations of FDG PET-CT
in
multiple myeloma and related clonal plasma cell proliferative disorders, such
as
smoldering multiple myeloma and plasmacytoma.
CI - © 2021. ISS.
FAU - Vicentini, Joao R T
AU - Vicentini JRT
AD - Division of Musculoskeletal Imaging and Intervention, Massachusetts General
Hospital and Harvard Medical School, Boston, USA.
FAU - Bredella, Miriam A
AU - Bredella MA
AD - Division of Musculoskeletal Imaging and Intervention, Massachusetts General
Hospital and Harvard Medical School, Boston, USA. [email protected].
AD - Division of Musculoskeletal Imaging and Intervention, Department of
Radiology,
Massachusetts General Hospital, 55 Fruit Street - YAW 6, Boston, MA, 02114,
USA.
[email protected].
LA - eng
PT - Journal Article
PT - Review
DEP - 20210404
PL - Germany
TA - Skeletal Radiol
JT - Skeletal radiology
JID - 7701953
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - *Multiple Myeloma/diagnostic imaging/pathology
MH - Neoplasm Recurrence, Local
MH - Neoplasm Staging
MH - Positron Emission Tomography Computed Tomography
MH - Positron-Emission Tomography
MH - Radiopharmaceuticals
OTO - NOTNLM
OT - FDG PET
OT - Monoclonal gammopathy of uncertain significance (MGUS)
OT - Multiple myeloma
OT - Plasmacytoma
EDAT- 2021/04/05 06:00
MHDA- 2021/12/01 06:00
CRDT- 2021/04/04 21:01
PHST- 2021/01/28 00:00 [received]
PHST- 2021/03/24 00:00 [accepted]
PHST- 2021/03/23 00:00 [revised]
PHST- 2021/04/05 06:00 [pubmed]
PHST- 2021/12/01 06:00 [medline]
PHST- 2021/04/04 21:01 [entrez]
AID - 10.1007/s00256-021-03771-2 [pii]
AID - 10.1007/s00256-021-03771-2 [doi]
PST - ppublish
SO - Skeletal Radiol. 2022 Jan;51(1):31-41. doi: 10.1007/s00256-021-03771-2. Epub
2021
Apr 4.

PMID- 33392351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR - 20210105
IS - 2322-5718 (Print)
IS - 2322-5726 (Electronic)
IS - 2322-5718 (Linking)
VI - 9
IP - 1
DP - 2021 Winter
TI - (18)F-FDG PET/CT in the Evaluation of Solitary Extramedullary Plasmacytoma: A
Case Series.
PG - 56-61
LID - 10.22038/AOJNMB.2020.49226.1335 [doi]
AB - The role of fluorine-18-fluorodeoxyglucose positron emission tomography/
computed
tomography ((18)F-FDG PET/CT) in patients with multiple myeloma (MM) and
other
plasma cell disorders is well-known. Solitary plasmacytoma (SP), an extremely
rare form within this entity accounting for approximately 4% of plasma cell
malignancies, can be classified as solitary bone plasmacytoma (SBP) or
solitary
extramedullary plasmacytoma (SEMP). Extramedullary plasmacytoma (EMP) is a
rare
neoplasm characterized by the monoclonal proliferation of plasma cells
outside
the bone marrow. Breast and craniocerebral regions are the uncommon sites of
the
presentations of EMP, rarely reported in the literature. The most frequent
site
of presentation is the upper airways. The EMPs have similar pathogenesis as
MM;
however, they differ in management as they are radiosensitive in nature, and
radiotherapy is the preferred treatment modality. As SEMP has a better
prognosis
than SPB with a lower conversion rate to MM, accurate staging is essential to
plan for the treatment. The (18)F-FDG PET/CT has higher sensitivity for the
evaluation of treatment response. In the present case series, it was aimed to
depict the role of (18)F-FDG PET/CT in newly diagnosed SEMP with different
sites
of origin to exclude further lesions leading to changes in the treatment plan
and
treatment response assessment.
CI - © 2021 mums.ac.ir All rights reserved.
FAU - Rachh, Swati
AU - Rachh S
AD - Department of Nuclear Medicine, Gujarat Cancer and Research Institute,
Asarwa,
Ahmedabad, Gujarat, India.
FAU - Puj, Ketul
AU - Puj K
AD - Department of Surgical Oncology, Gujarat Cancer and Research Institute,
Asarwa,
Ahmedabad, Gujarat, India.
FAU - Parikh, Ankita
AU - Parikh A
AD - Department of Radiation Oncology, Gujarat Cancer and Research Institute,
Asarwa,
Ahmedabad,Gujarat, India.
LA - eng
PT - Case Reports
PL - Iran
TA - Asia Ocean J Nucl Med Biol
JT - Asia Oceania journal of nuclear medicine & biology
JID - 101611092
PMC - PMC7701227
OTO - NOTNLM
OT - FDG PET/CT
OT - Radiation therapy. Management
OT - Solitary extramedullary plasmacytoma
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:31
PHST- 2021/01/04 05:31 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.22038/AOJNMB.2020.49226.1335 [doi]
PST - ppublish
SO - Asia Ocean J Nucl Med Biol. 2021 Winter;9(1):56-61. doi:
10.22038/AOJNMB.2020.49226.1335.

PMID- 33534256
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Print)
IS - 0363-9762 (Linking)
VI - 46
IP - 4
DP - 2021 Apr 1
TI - Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared
With
Skeletal Survey for Initial Staging and Response at End-of-Treatment
Evaluation
of Patients With Multiple Myeloma.
PG - 310-322
LID - 10.1097/RLU.0000000000003512 [doi]
AB - PURPOSE: To compare the agreement between whole-body (WB) magnetic resonance
(MR)
imaging, 18F-FDG PET/CT, and skeletal survey (SS) in patients with multiple
myeloma (MM) for diagnosis, initial staging, response evaluation, and early
detection of complications. METHODS: This is a retrospective cohort study
including MM patients who were diagnosed, treated, and followed in 2
institutions. These patients were studied with SS, WB-MR, and/or 18F-FDG
PET/CT.
We studied bone lesions by anatomical locations and analyzed the concordance
between SS and a tomographic technique (WB-MR or 18F-FDG PET/CT) and between
both
tomographic techniques (WB-MR and PET/CT). RESULTS: Forty-four MM patients
with a
mean age of 62.6 years (range, 38-85 years) were included from January 2012
to
February 2016. Whole-body MR and 18F-FDG PET/CT found more lesions than SS in
every location except in the skull. Concordance between WB-MR and 18F-FDG
PET/CT
was either good or excellent in most of the locations and in plasmacytoma
studies. However, WB-MR was better than 18F-FDG PET/CT in the study of
complications (medullar compression and vascular necrosis). CONCLUSIONS: Our
results suggest the study of MM patients should include WB-MR and/or 18F-FDG
PET/CT, whereas SS is only useful for the skull. Whole-body MR and 18F-FDG
PET/CT
are complementary techniques, because both of them show good concordance in
almost every location. It is still necessary to individualize the indication
of
 each technique according to patient characteristics.
CI - Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Gómez León, Nieves
AU - Gómez León N
FAU - Aguado Bueno, Beatriz
AU - Aguado Bueno B
AD - Department of Haematology, University Hospital la Princesa of Madrid.
FAU - Herreros Pérez, María
AU - Herreros Pérez M
FAU - León Ramírez, Luisa F
AU - León Ramírez LF
AD - Department of Nuclear Medicine, University Hospital Rey Juan Carlos,
Móstoles,
Madrid, Spain.
FAU - Alegre, Adrián
AU - Alegre A
AD - Department of Haematology, University Hospital la Princesa of Madrid.
FAU - Colletti, Patrick M
AU - Colletti PM
AD - Department of Radiology, Keck School of Medicine of USC, Los Angeles, CA.
FAU - Rubello, Domenico
AU - Rubello D
AD - Department of Nuclear Medicine and PET Unit, Rovigo Hospital, Rovigo, Italy.
FAU - Carreras, José L
AU - Carreras JL
AD - Department of Nuclear Medicine, University Hospital Clínico San Carlos,
Madrid.
FAU - Delgado Bolton, Roberto C
AU - Delgado Bolton RC
AD - Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University
Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR),
Logroño, La Rioja, Spain.
LA - eng
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Adult
MH - Aged
MH - Aged, 80 and over
MH - Female
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - *Magnetic Resonance Imaging
MH - Male
MH - Middle Aged
MH - Multiple Myeloma/diagnostic imaging/*pathology/*therapy
MH - *Positron Emission Tomography Computed Tomography
MH - Retrospective Studies
MH - Skeleton/*diagnostic imaging
MH - Treatment Outcome
MH - *Whole Body Imaging
PMC - PMC7938909
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2021/02/04 06:00
MHDA- 2021/04/07 06:00
CRDT- 2021/02/03 12:27
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2021/02/03 12:27 [entrez]
AID - 00003072-202104000-00006 [pii]
AID - CNM_200034 [pii]
AID - 10.1097/RLU.0000000000003512 [doi]
PST - ppublish
SO - Clin Nucl Med. 2021 Apr 1;46(4):310-322. doi: 10.1097/RLU.0000000000003512.

PMID- 34901966
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR - 20220117
IS - 1790-5427 (Print)
IS - 1790-5427 (Linking)
VI - 24
IP - 3
DP - 2021 Sep-Dec
TI - Uncommon solitary nasal extramedullary plasmacytoma detected by (18)F-FDG
PET/CT.
PG - 265-266
LID - 10.1967/s002449912409 [doi]
AB - Extramedullary plasmacytoma (EMP) is an uncommon neoplastic proliferation of
monoclonal plasma cells. Despite having a better prognosis and lower
conversion
rate to multiple myeloma in comparison to solitary bone plasmacytoma, EMP
diagnosis can be challenging. Fluorine-18-fluorodeoxyglucose positron
emission
tomography/computed tomography ((18)F-FDG PET/CT) certainly has an
established
role in EMP diagnostic workup. Herein, we describe a rare case of nasal
cavity
EMP, highlighting (18)F-FDG PET/CT potential in the detection of EMP
occurring in
atypical sites and providing a useful comparison in the differential
diagnosis
with other (18)F-FDG avid nasal pathologies.
FAU - Urso, Luca
AU - Urso L
AD - Nuclear Medicine Unit, Oncological Medical and Specialists Department,
University
Hospital of Ferrara, Ferrara, Italy. Via Aldo Moro 8, CAP 44124, Ferrara,
Italy.
[email protected].
FAU - Ortolan, Naima
AU - Ortolan N
FAU - Panareo, Stefano
AU - Panareo S
FAU - Stefanelli, Antonio
AU - Stefanelli A
FAU - Cuneo, Antonio
AU - Cuneo A
FAU - Bartolomei, Mirco
AU - Bartolomei M
LA - eng
PT - Case Reports
PT - Journal Article
DEP - 20211217
PL - Greece
TA - Hell J Nucl Med
JT - Hellenic journal of nuclear medicine
JID - 101257471
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - *Plasmacytoma/diagnostic imaging
MH - Positron Emission Tomography Computed Tomography
MH - Positron-Emission Tomography
MH - Radiopharmaceuticals
EDAT- 2021/12/14 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/12/13 18:21
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/12/13 18:21 [entrez]
AID - s002449912409 [pii]
AID - 10.1967/s002449912409 [doi]
PST - ppublish
SO - Hell J Nucl Med. 2021 Sep-Dec;24(3):265-266. doi: 10.1967/s002449912409. Epub
2021 Dec 17.

PMID- 32349089
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR - 20210206
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 45
IP - 6
DP - 2020 Jun
TI - FDG PET/CT Imaging of Pancreatic Plasmacytoma.
PG - 489-491
LID - 10.1097/RLU.0000000000003019 [doi]
AB - A 56-year-old man underwent F-FDG PET/CT to evaluate possible pancreatic
cancer,
which was revealed by CT. The images showed a solid lesion with peripherally
increased FDG activity in the tail of the pancreas, as well as hypermetabolic
lesions in the lumbar spine and rib. Pathological examination following
lumbar
biopsy demonstrated multiple myeloma. Five months after chemotherapy, follow-
up
FDG PET/CT showed cystic change in the pancreatic lesion without elevated
metabolism.
FAU - Huang, Wen-Shan
AU - Huang WS
AD - From the Departments of Nuclear Medicine.
FAU - Zheng, Yongjiang
AU - Zheng Y
AD - Hematology, The Third Affiliated Hospital of Sun Yat-Sen University,
Guangzhou,
People's Republic of China.
FAU - Chen, Jia-Wen
AU - Chen JW
AD - From the Departments of Nuclear Medicine.
FAU - Zhang, Gui-Xiong
AU - Zhang GX
AD - From the Departments of Nuclear Medicine.
FAU - Xu, Jie-Hua
AU - Xu JH
AD - From the Departments of Nuclear Medicine.
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Biopsy
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - Male
MH - Middle Aged
MH - Multiple Myeloma/diagnostic imaging/pathology
MH - Pancreatic Neoplasms/*diagnostic imaging/pathology
MH - Plasmacytoma/*diagnostic imaging/pathology
MH - *Positron Emission Tomography Computed Tomography
EDAT- 2020/04/30 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 00003072-202006000-00023 [pii]
AID - 10.1097/RLU.0000000000003019 [doi]
PST - ppublish
SO - Clin Nucl Med. 2020 Jun;45(6):489-491. doi: 10.1097/RLU.0000000000003019.

PMID- 32332314
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR - 20210206
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 45
IP - 6
DP - 2020 Jun
TI - Rib Plasmacytoma With Unusual Sunburst Periosteal Reaction.
PG - 461-462
LID - 10.1097/RLU.0000000000003030 [doi]
AB - A 39-year-old man presented with progressive painful swelling on the left
chest
since 6 months. Examination revealed osseous consistency mass. CT of the
thorax
suggested mass arising from left fourth rib with intrathoracic and
extrathoracic
soft tissue components. It had extensive sunburst periosteal reaction
consistent
with primary malignant bone tumor. True cut biopsy revealed plasmacytoma.
Routine
 hematological, biochemical, and bone marrow examinations were normal. Patient
referred for whole-body F-FDG PET/CT to look for skeletal and bone marrow
lesions. It revealed intensely metabolic left fourth rib lesion with
periosteal
reaction and no other lesion in the rest of the body.
FAU - Singh, Vijay
AU - Singh V
AD - From the Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute
of
Medical Sciences, Lucknow, India.
FAU - Suraj, Ajay Kumar
AU - Suraj AK
FAU - Mishra, Vineet
AU - Mishra V
FAU - Ora, Manish
AU - Ora M
FAU - Gambhir, Sanjay
AU - Gambhir S
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Adult
MH - Biopsy
MH - Bone Neoplasms/diagnostic imaging/pathology/*physiopathology
MH - Fluorodeoxyglucose F18
MH - Humans
MH - Male
MH - *Osteogenesis
MH - Plasmacytoma/diagnostic imaging/pathology/*physiopathology
MH - Positron Emission Tomography Computed Tomography
MH - Ribs/diagnostic imaging/*pathology/*physiopathology
EDAT- 2020/04/26 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - 00003072-202006000-00013 [pii]
AID - 10.1097/RLU.0000000000003030 [doi]
PST - ppublish
SO - Clin Nucl Med. 2020 Jun;45(6):461-462. doi: 10.1097/RLU.0000000000003030.

PMID- 32149790
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR - 20210204
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 45
IP - 5
DP - 2020 May
TI - 18F-FDG PET/CT Findings in a Patient With Neutrophilic Leukemoid Reaction
 Associated With Multiple Myeloma.
PG - 405-406
LID - 10.1097/RLU.0000000000002999 [doi]
AB - F-FDG PET/CT was performed on a 48-year-old woman with leukocytosis (white
blood
cell count 57.10 × 10/L, 84.0% neutrophils) and monoclonal gammopathy to
investigate the possibility of reactive neutrophilia secondary to
plasmacytoma.
On the background of skeletal "superscan," the maximum intensity projection
image
of PET demonstrated the highest metabolic region in the left sacrum, which
was
confirmed as an osteolytic lesion by CT. Biopsy of the sacral lesion revealed
a
plasma cell myeloma, indicating the diagnosis of neutrophilic leukemoid
reaction
associated with multiple myeloma. The white blood cell counts dramatically
dropped to the normal level after 1 cycle of chemotherapy for multiple
myeloma.
FAU - An, Caixia
AU - An C
AD - From the Departments of Nuclear Medicine.
FAU - Zhai, Luoping
AU - Zhai L
AD - From the Departments of Nuclear Medicine.
FAU - Geng, Huixia
AU - Geng H
AD - From the Departments of Nuclear Medicine.
FAU - Wang, Pingzhi
AU - Wang P
AD - Rehabilitation, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital,
Taiyuan, Shanxi, China.
FAU - Zhang, Wanchun
AU - Zhang W
AD - From the Departments of Nuclear Medicine.
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Female
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - Leukemoid Reaction/*complications/*diagnostic imaging
MH - Middle Aged
MH - Multiple Myeloma/*complications
MH - Plasmacytoma/complications/pathology
MH - *Positron Emission Tomography Computed Tomography
EDAT- 2020/03/10 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/03/10 06:00
PHST- 2020/03/10 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/03/10 06:00 [entrez]
AID - 00003072-202005000-00020 [pii]
AID - 10.1097/RLU.0000000000002999 [doi]
PST - ppublish
SO - Clin Nucl Med. 2020 May;45(5):405-406. doi: 10.1097/RLU.0000000000002999.

PMID- 33630796
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 46
IP - 10
DP - 2021 Oct 1
TI - Multiple Myeloma Presenting as Disseminated Osteoblastic Lesions With Intense
18F-FDG Uptake on PET/CT.
PG - e492-e495
LID - 10.1097/RLU.0000000000003542 [doi]
AB - A 42-year-old woman presented with numbness and weakness in the lower limbs.
The
radiograph, MRI, and 99mTc-MDP bone scintigraphy revealed multiple bone
lesions.
The lesions were sclerotic on radiograph. Subsequent 18F-FDG PET/CT showed
the
lesions were disseminated and had intense 18F-FDG uptake. Monoclonal lambda
plasmacytoma was confirmed after CT-guided biopsy of the third lumbar
vertebral
lesion. The laboratory data also showed a monoclonal immunoglobulin G lambda
protein in serum and urine immunofixation. The patient was diagnosed as
multiple
myeloma finally. Multiple myeloma should be in the differential diagnosis
scope
of multiple osteoblastic lesions with intense 18F-FDG uptake on PET/CT.
CI - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wang, Yueqi
AU - Wang Y
AD - From the Department of Nuclear Medicine, West China Hospital of Sichuan
University, Chengdu, People's Republic of China.
FAU - Fan, Qiuping
AU - Fan Q
FAU - Su, Minggang
AU - Su M
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Adult
MH - Female
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - *Multiple Myeloma/diagnostic imaging
MH - Positron Emission Tomography Computed Tomography
MH - Positron-Emission Tomography
MH - Radiopharmaceuticals
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2021/02/26 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/02/25 17:15
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/02/25 17:15 [entrez]
AID - 00003072-202110000-00027 [pii]
AID - 10.1097/RLU.0000000000003542 [doi]
PST - ppublish
SO - Clin Nucl Med. 2021 Oct 1;46(10):e492-e495. doi:
10.1097/RLU.0000000000003542.

PMID- 37883218
OWN - NLM
STAT- MEDLINE
DCOM- 20231108
LR - 20231108
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 48
IP - 12
DP - 2023 Dec 1
TI - FDG PET/CT Image of Extramedullary Plasmacytoma in the Anterior Mediastinum.
PG - e603-e604
LID - 10.1097/RLU.0000000000004923 [doi]
AB - Extramedullary plasmacytoma in the anterior mediastinum is very rare. We
report
FDG PET/CT findings of anterior mediastinum extramedullary plasmacytoma in a
54-year-old woman. On FDG PET/CT, it presented as a solitary anterior
mediastinum
mass with increased FDG uptake. The final pathology supported a diagnosis of
extramedullary plasmacytoma. This case hints us that extramedullary
plasmacytoma
should be regarded as a differential diagnosis when we encounter a solitary
anterior mediastinum mass with intense FDG uptake.
CI - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Xiao, Liu
AU - Xiao L
AD - From the Department of Nuclear Medicine, West China Hospital, Sichuan
University,
Chengdu, Sichuan Province, People's Republic of China.
FAU - Li, Lin
AU - Li L
LA - eng
PT - Case Reports
PT - Journal Article
DEP - 20231025
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Female
MH - Humans
MH - Middle Aged
MH - *Plasmacytoma/pathology
MH - Positron Emission Tomography Computed Tomography
MH - Fluorodeoxyglucose F18
MH - Mediastinum/pathology
MH - Positron-Emission Tomography
COIS- Conflicts of interest and sources of funding: none declared. This article was
supported by the Natural Science Foundation of Sichuan Province (grant
2023NSFSC5333).
EDAT- 2023/10/26 18:42
MHDA- 2023/11/08 06:43
CRDT- 2023/10/26 12:33
PHST- 2023/11/08 06:43 [medline]
PHST- 2023/10/26 18:42 [pubmed]
PHST- 2023/10/26 12:33 [entrez]
AID - 00003072-990000000-00781 [pii]
AID - 10.1097/RLU.0000000000004923 [doi]
PST - ppublish
SO - Clin Nucl Med. 2023 Dec 1;48(12):e603-e604. doi:
10.1097/RLU.0000000000004923.
Epub 2023 Oct 25.

PMID- 31754820
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR - 20210623
IS - 1432-0932 (Electronic)
IS - 0940-6719 (Print)
IS - 0940-6719 (Linking)
VI - 29
IP - 5
DP - 2020 May
TI - Diagnosis of spinal lesions using perfusion parameters measured by DCE-MRI
and
metabolism parameters measured by PET/CT.
PG - 1061-1070
LID - 10.1007/s00586-019-06213-9 [doi]
AB - PURPOSE: To investigate the correlation of parameters measured by
dynamic-contrast-enhanced MRI (DCE-MRI) and (18)F-FDG PET/CT in spinal
tumors,
and their role in differential diagnosis. METHODS: A total of 49 patients
with
pathologically confirmed spinal tumors, including 38 malignant, six benign
and
five borderline tumors, were analyzed. The MRI and PET/CT were done within
3 days, before biopsy. On MRI, the ROI was manually placed on area showing
the
strongest enhancement to measure pharmacokinetic parameters K(trans) and
k(ep).
On PET, the maximum standardized uptake value SUV(max) was measured. The
parameters in different histological groups were compared. ROC was performed
to
differentiate between the two largest subtypes, metastases and plasmacytomas.
Spearman rank correlation was performed to compare DCE-MRI and PET/CT
parameters.
RESULTS: The K(trans), k(ep) and SUV(max) were not statistically different
among
malignant, benign and borderline groups (P = 0.95, 0.50, 0.11). There was no
significant correlation between K(trans) and SUV(max) (r = - 0.20, P = 0.18), or
between k(ep) and SUV(max) (r = - 0.16, P = 0.28). The k(ep) was significantly
 higher in plasmacytoma than in metastasis (0.78 ± 0.17 vs. 0.61 ± 0.18,
P = 0.02); in contrast, the SUV(max) was significantly lower in plasmacytoma
than
in metastasis (5.58 ± 2.16 vs. 9.37 ± 4.26, P = 0.03). In differential diagnosis,
the AUC of k(ep) and SUV(max) was 0.79 and 0.78, respectively. CONCLUSIONS:
The
vascular parameters measured by DCE-MRI and glucose metabolism measured by
PET/CT
from the most aggressive tumor area did not show a significant correlation.
The
results suggest they provide complementary information reflecting different
aspects of the tumor, which may aid in diagnosis of spinal lesions. These
slides
can be retrieved under Electronic Supplementary Material.
FAU - Zhang, Jiahui
AU - Zhang J
AD - Department of Radiology, Peking University Third Hospital, 49 North Garden
Road,
Haidian District, Beijing, 100191, People's Republic of China.
FAU - Chen, Yongye
AU - Chen Y
AD - Department of Radiology, Peking University Third Hospital, 49 North Garden
Road,
Haidian District, Beijing, 100191, People's Republic of China.
FAU - Zhang, Yanyan
AU - Zhang Y
AD - Department of Nuclear Medicine, Peking University Third Hospital, Beijing,
People's Republic of China.
FAU - Zhang, Enlong
AU - Zhang E
AD - Department of Radiology, Peking University Third Hospital, 49 North Garden
Road,
Haidian District, Beijing, 100191, People's Republic of China.
FAU - Yu, Hon J
AU - Yu HJ
AD - Department of Radiological Sciences, Center for Functional Onco-Imaging,
University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA.
FAU - Yuan, Huishu
AU - Yuan H
AD - Department of Radiology, Peking University Third Hospital, 49 North Garden
Road,
Haidian District, Beijing, 100191, People's Republic of China.
FAU - Zhang, Yang
AU - Zhang Y
AD - Department of Radiological Sciences, Center for Functional Onco-Imaging,
University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA.
FAU - Su, Min-Ying
AU - Su MY
AD - Department of Radiological Sciences, Center for Functional Onco-Imaging,
University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA.
[email protected].
FAU - Lang, Ning
AU - Lang N
AUID- ORCID: 0000-0001-7501-1773
AD - Department of Radiology, Peking University Third Hospital, 49 North Garden
Road,
Haidian District, Beijing, 100191, People's Republic of China.
[email protected].
LA - eng
GR - R01 CA127927/CA/NCI NIH HHS/United States
GR - BYSY2018007/Key Clinical Projects of the Peking University Third
Hospital/International
GR - R21 CA208938/CA/NCI NIH HHS/United States
GR - 81701648/National Natural Science Foundation of China/International
GR - P30 CA062203/CA/NCI NIH HHS/United States
GR - 81871326/National Natural Science Foundation of China/International
PT - Journal Article
PT - Research Support, N.I.H., Extramural
PT - Research Support, Non-U.S. Gov't
DEP - 20191121
PL - Germany
TA - Eur Spine J
JT - European spine journal : official publication of the European Spine Society,
the
European Spinal Deformity Society, and the European Section of the Cervical
Spine
Research Society
JID - 9301980
RN - 0 (Contrast Media)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - *Contrast Media
MH - Fluorodeoxyglucose F18
MH - Humans
MH - Magnetic Resonance Imaging
MH - Perfusion
MH - *Positron Emission Tomography Computed Tomography
PMC - PMC7709817
MID - NIHMS1648746
OTO - NOTNLM
OT - Magnetic resonance imaging
OT - Positron emission tomography/computed tomography
OT - Spinal neoplasms
EDAT- 2019/11/23 06:00
MHDA- 2021/06/24 06:00
CRDT- 2019/11/23 06:00
PHST- 2019/05/08 00:00 [received]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/05/08 00:00 [revised]
PHST- 2019/11/23 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2019/11/23 06:00 [entrez]
AID - 10.1007/s00586-019-06213-9 [pii]
AID - 10.1007/s00586-019-06213-9 [doi]
PST - ppublish
SO - Eur Spine J. 2020 May;29(5):1061-1070. doi: 10.1007/s00586-019-06213-9. Epub
2019
Nov 21.

PMID- 35307720
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 47
IP - 5
DP - 2022 May 1
TI - Extramedullary Plasmacytoma: Hepatic Lesions and Enlarged Lymph Nodes With
Intense 18F-FDG Uptake Mimicking Metastases.
PG - 422-424
LID - 10.1097/RLU.0000000000004096 [doi]
AB - A 66-year-old woman having intermittent abdominal distention for 2 months was
referred to our hospital. An enhanced abdominal CT scan showed multiple
hepatic
lesions, suspected of metastases. An 18F-FDG PET/CT scan, which was performed
to
seek primary tumor, showed multiple lesions with intense 18F-FDG uptake in
the
liver and lymph nodes located in cardiophrenic angle, abdominal cavity, and
retroperitoneal space. All 18F-FDG-avid lesions were suspected of metastases.
However, no suspected primary tumor was identified by the 18F-FDG PET/CT
scan,
which prompted the liver biopsy. Pathologic analysis revealed the presence of
plasmacytoma.
CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wu, Fengyu
AU - Wu F
AD - From the PET/CT Center, Department of Nuclear Medicine, Affiliated Hospital
of
Qingdao University, Qingdao, China.
FAU - Yu, Mingming
AU - Yu M
FAU - Shi, Bin
AU - Shi B
FAU - Yu, Qian
AU - Yu Q
FAU - Wang, Zhenguang
AU - Wang Z
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Aged
MH - Female
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - Lymph Nodes/diagnostic imaging
MH - *Plasmacytoma/diagnostic imaging
MH - Positron Emission Tomography Computed Tomography
MH - Tomography, X-Ray Computed
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2022/03/22 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/03/21 05:44
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2022/03/21 05:44 [entrez]
AID - 00003072-202205000-00006 [pii]
AID - 10.1097/RLU.0000000000004096 [doi]
PST - ppublish
SO - Clin Nucl Med. 2022 May 1;47(5):422-424. doi: 10.1097/RLU.0000000000004096.

PMID- 35439181
OWN - NLM
STAT- MEDLINE
DCOM- 20220711
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 47
IP - 8
DP - 2022 Aug 1
TI - PET/CT Imaging of Hemorrhagic Pseudotumor Arising From Treated Plasmacytoma.
PG - e565-e567
LID - 10.1097/RLU.0000000000004233 [doi]
AB - Hemorrhagic pseudotumor occurs in approximately 1% to 2% of patients with
hemophilia. This lesion is exceptionally rare in nonhemophiliac individuals.
The
authors present a case of treated right ischial plasmacytoma with a
progressively
enlarging expansile hemorrhagic pseudotumor, documented on 18 F-FDG PET/CT
and
MRI and confirmed by histology.
CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Cumsky, Jameson L
AU - Cumsky JL
AD - From the Department of Radiology, Mayo Clinic, Scottsdale, AZ.
FAU - Nguyen, Ba Duong
AU - Nguyen BD
LA - eng
PT - Case Reports
PT - Journal Article
DEP - 20220419
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Fluorodeoxyglucose F18
MH - Humans
MH - *Plasmacytoma/diagnostic imaging/pathology
MH - *Positron Emission Tomography Computed Tomography/methods
MH - Positron-Emission Tomography
MH - Radiopharmaceuticals
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2022/04/20 06:00
MHDA- 2022/07/12 06:00
CRDT- 2022/04/19 17:11
PHST- 2022/04/20 06:00 [pubmed]
PHST- 2022/07/12 06:00 [medline]
PHST- 2022/04/19 17:11 [entrez]
AID - 00003072-202208000-00036 [pii]
AID - 10.1097/RLU.0000000000004233 [doi]
PST - ppublish
SO - Clin Nucl Med. 2022 Aug 1;47(8):e565-e567. doi: 10.1097/RLU.0000000000004233.
Epub 2022 Apr 19.
PMID- 37962177
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR - 20240207
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 49
IP - 1
DP - 2024 Jan 1
TI - Extramedullary Plasmacytoma of the Retroperitoneum Detected on 18 F-FDG
PET/CT.
PG - 98-100
LID - 10.1097/RLU.0000000000004939 [doi]
AB - Solitary retroperitoneal extramedullary plasmacytoma is a rare neoplasm. A
67-year-old man presented with abdominal pain and left leg weakness.
Abdominal CT
revealed a large mass in the left retroperitoneum, which demonstrated
increased
metabolic activity on subsequent 18 F-FDG PET/CT imaging. Furthermore, the
patient's serum protein electrophoresis showed positive M-protein results.
Pathological examination of the biopsied specimen confirmed the diagnosis of
extramedullary plasmacytoma.
CI - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Deng, Yan
AU - Deng Y
FAU - Deng, Ying
AU - Deng Y
AD - Department of Nuclear Medicine, Hospital of Chengdu University of Traditional
Chinese Medicine.
FAU - Zhang, Wei
AU - Zhang W
AD - Department of Nuclear Medicine, Sichuan Provincial People's Hospital,
University
of Electronic Science and Technology of China, Chengdu, China.
FAU - Lei, Xiaoping
AU - Lei X
LA - eng
PT - Case Reports
PT - Journal Article
DEP - 20231110
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Male
MH - Humans
MH - Aged
MH - Positron Emission Tomography Computed Tomography
MH - Fluorodeoxyglucose F18
MH - *Plasmacytoma/diagnostic imaging/pathology
MH - Positron-Emission Tomography
MH - Tomography, X-Ray Computed
MH - *Bone Neoplasms
COIS- Conflicts of interest and sources of funding: No competing financial
interests
exist. This study was funded by the Natural Science Foundation of Sichuan
 Province grant no. 2023NSFSC0635.
EDAT- 2023/11/14 12:42
MHDA- 2023/12/17 09:43
CRDT- 2023/11/14 07:53
PHST- 2023/12/17 09:43 [medline]
PHST- 2023/11/14 12:42 [pubmed]
PHST- 2023/11/14 07:53 [entrez]
AID - 00003072-202401000-00022 [pii]
AID - 10.1097/RLU.0000000000004939 [doi]
PST - ppublish
SO - Clin Nucl Med. 2024 Jan 1;49(1):98-100. doi: 10.1097/RLU.0000000000004939.
Epub
2023 Nov 10.

PMID- 35020646
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 47
IP - 4
DP - 2022 Apr 1
TI - Rare Distribution of Sclerotic Bony Lesions in Multiple Myeloma: A Case
Report.
PG - e344-e345
LID - 10.1097/RLU.0000000000003967 [doi]
AB - A 66-year-old man was referred to our hospital due to a newly discovered left
chest wall mass, which was diagnosed as plasmacytoma on biopsy. The patient
underwent 18F-FDG PET/CT scanning before treatment. PET imaging revealed
intense
FDG signal in osseous lesions, and the CT showed most of the lesions were
osteoblastic. The osseous lesions were predominantly localized to the
humerus,
femur, tibia, and phalanx of toe.
CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wang, Yuhua
AU - Wang Y
AD - From the Department of Nuclear Medicine, Shanxi Bethune Hospital, Shanxi
Academy
of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical
University, Taiyuan; and Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China.
FAU - Liu, Ye
AU - Liu Y
FAU - Ma, Le
AU - Ma L
FAU - An, Caixia
AU - An C
FAU - Zhang, Wanchun
AU - Zhang W
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Aged
MH - Fluorodeoxyglucose F18
MH - Humans
MH - Male
MH - *Multiple Myeloma/complications/diagnostic imaging
MH - *Plasmacytoma
MH - Positron Emission Tomography Computed Tomography
MH - Positron-Emission Tomography
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2022/01/13 06:00
MHDA- 2022/03/05 06:00
CRDT- 2022/01/12 17:24
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2022/01/12 17:24 [entrez]
AID - 00003072-202204000-00035 [pii]
AID - 10.1097/RLU.0000000000003967 [doi]
PST - ppublish
SO - Clin Nucl Med. 2022 Apr 1;47(4):e344-e345. doi: 10.1097/RLU.0000000000003967.

PMID- 35025778
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 47
IP - 3
DP - 2022 Mar 1
TI - Bilateral Testicular Mass Presenting as a Rare Manifestation of
Extramedullary
Plasmacytoma on 18F-FDG PET/CT.
PG - e296-e297
LID - 10.1097/RLU.0000000000004043 [doi]
AB - We present the case of a 48-year-old man diagnosed with metastatic Ewing
sarcoma
who was referred for 18F-FDG PET/CT for treatment response evaluation
following
chemoradiotherapy. The patient also had complaints of new-onset testicular
swelling at the time of imaging. Although the metastatic bone disease showed
a
complete metabolic response to treatment, 18F-FDG PET/CT demonstrated
significantly increased metabolic activity in bilateral testicular mass.
Consequently, the patient underwent bilateral orchiectomy, and
histopathologic
examination revealed bilateral testicular plasmacytoma, a rare manifestation
of
extramedullary plasmacytoma.
CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Civan, Caner
AU - Civan C
AD - From the Departments of Nuclear Medicine.
FAU - Apaydin Arikan, Evsen
AU - Apaydin Arikan E
AD - Pathology.
FAU - Has Simsek, Duygu
AU - Has Simsek D
AD - From the Departments of Nuclear Medicine.
FAU - Sanli, Oner
AU - Sanli O
AD - Urology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
FAU - Kuyumcu, Serkan
AU - Kuyumcu S
AD - From the Departments of Nuclear Medicine.
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - Fluorodeoxyglucose F18
MH - Humans
MH - Male
MH - Middle Aged
MH - *Plasmacytoma/diagnostic imaging
MH - Positron Emission Tomography Computed Tomography
MH - Positron-Emission Tomography
MH - *Sarcoma, Ewing
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2022/01/14 06:00
MHDA- 2022/02/04 06:00
CRDT- 2022/01/13 17:24
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2022/01/13 17:24 [entrez]
AID - 00003072-202203000-00053 [pii]
AID - 10.1097/RLU.0000000000004043 [doi]
PST - ppublish
SO - Clin Nucl Med. 2022 Mar 1;47(3):e296-e297. doi: 10.1097/RLU.0000000000004043.

PMID- 33630797
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR - 20230925
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 46
IP - 8
DP - 2021 Aug 1
TI - Detection of Nasal Solitary Extramedullary Plasmacytoma on 18F-FDG PET/CT
Imaging.
PG - 677-678
LID - 10.1097/RLU.0000000000003544 [doi]
AB - A 46-year-old man presented with a 3-month history of epistaxis. CT and MRI
scan
showed a soft tissue mass in the left nasal cavity. An excisional biopsy of
the
mass revealed extramedullary plasmacytoma. 18F-FDG PET/CT showed intense
activity
in the region of the left nasal cavity but no other FDG-avid lesions.
Additional
 workups did not reveal any evidence of systematic disease. Based on these
findings, the patient was diagnosed as having solitary nasal extramedullary
plasmacytoma. He received the local radiation therapy. During the 3-month
follow-up, his symptom was relieved.
CI - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wu, Junhao
AU - Wu J
FAU - Rao, Zijuan
AU - Rao Z
FAU - Jiang, Guohao
AU - Jiang G
FAU - Liu, Huipan
AU - Liu H
FAU - Zhang, Chunyin
AU - Zhang C
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB - IM
MH - *Fluorodeoxyglucose F18
MH - Humans
MH - Male
MH - Middle Aged
MH - Nose Neoplasms/*diagnostic imaging
MH - Plasmacytoma/*diagnostic imaging
MH - *Positron Emission Tomography Computed Tomography
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2021/02/26 06:00
MHDA- 2021/07/08 06:00
CRDT- 2021/02/25 17:15
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2021/02/25 17:15 [entrez]
AID - 00003072-202108000-00017 [pii]
AID - 10.1097/RLU.0000000000003544 [doi]
PST - ppublish
SO - Clin Nucl Med. 2021 Aug 1;46(8):677-678. doi: 10.1097/RLU.0000000000003544.

PMID- 31135522
OWN - NLM
STAT- MEDLINE
DCOM- 20190822
LR - 20190822
IS - 1536-0229 (Electronic)
IS - 0363-9762 (Linking)
VI - 44
IP - 7
DP - 2019 Jul
TI - The Finding of the "Mini Brain" May Not Be a Unique Anatomic Appearance of
Spinal
Plasmacytoma.
PG - 596-598
LID - 10.1097/RLU.0000000000002632 [doi]
AB - MRI and F-FDG PET/CT were performed on a 37-year-old man who was suspected
with
malignant spinal tumor on x-ray examination. An FDG-avid expansile lytic
lesion
was found in his T12 vertebra. The lesion showed a characteristic "mini-
brain"
appearance on MRI and CT. This extremely high specificity sign and consistent
manifestation on PET image indicated plasmacytoma as the most optimal
diagnosis.
But finally, a giant cell tumor was confirmed after surgery. The case
cautions
that the specificity of the diagnostic characteristics of "mini-brain" sign
for
plasmacytoma or multiple myeloma may not be as high as previously reported.
FAU - Zhong, Xiao
AU - Zhong X
AD - From the Department of Nuclear Medicine, West China Hospital of Sichuan
University, Chengdu, Sichuan, People's Republic of China.
FAU - Jia, Zhiyun
AU - Jia Z
FAU - Su, Minggang
AU - Su M
LA - eng
PT - Case Reports
PT - Journal Article
PL - United States
TA - Clin Nucl Med
JT - Clinical nuclear medicine
JID - 7611109
RN - 0 (Radiopharmaceuticals)
RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
MH - Adult
MH - Diagnosis, Differential
MH - Fluorodeoxyglucose F18
MH - Giant Cell Tumors/*diagnostic imaging/pathology
MH - Humans
MH - Male
MH - Multiple Myeloma/*diagnostic imaging/pathology
MH - Plasmacytoma/*diagnostic imaging/pathology
MH - *Positron Emission Tomography Computed Tomography
MH - Radiopharmaceuticals
MH - Spinal Cord Neoplasms/*diagnostic imaging/pathology
EDAT- 2019/05/29 06:00
MHDA- 2019/08/23 06:00
CRDT- 2019/05/29 06:00
PHST- 2019/05/29 06:00 [pubmed]
PHST- 2019/08/23 06:00 [medline]
PHST- 2019/05/29 06:00 [entrez]
AID - 10.1097/RLU.0000000000002632 [doi]
PST - ppublish
SO - Clin Nucl Med. 2019 Jul;44(7):596-598. doi: 10.1097/RLU.0000000000002632.